OncoMatch/Clinical Trials/NCT06551324
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Is NCT06551324 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including PF-06821497 and Docetaxel for metastatic castrate resistant prostate cancer (mcrpc).
Treatment: PF-06821497 · Docetaxel · Enzalutamide — Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment. The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus enzalutamide versus physician's choice of enzalutamide or docetaxel.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: abiraterone acetate (abiraterone acetate) — mCSPC or first line mCRPC
evidence of disease progression on treatment with abiraterone acetate in the mCSPC setting or first line mCRPC setting is required
Cannot have received: cytotoxic chemotherapy
Exception: Docetaxel allowed for mCSPC if no progression during or within 3 months of treatment
Prior treatment for prostate cancer at any stage with any cytotoxic chemotherapy...with the following exceptions: Docetaxel treatment is allowed for mCSPC, as long as no signs of failure, or disease progression occurred during treatment or within 3 months of treatment completion.
Cannot have received: radioligand therapy (177Lu-PSMA-617, radium 223)
Prior treatment for prostate cancer at any stage with...radioligand therapy (i.e. 177Lu-PSMA-617, radium 223)
Cannot have received: androgen receptor signaling inhibitor (enzalutamide, apalutamide, darolutamide)
Exception: First-generation antiandrogen agents allowed if discontinued prior to first dose of study intervention
Prior treatment for prostate cancer at any stage with...androgen receptor signaling inhibitors (ARSi) including enzalutamide, apalutamide, darolutamide...with the following exceptions: Treatment with first-generation antiandrogen agents, if discontinued prior to first dose of study intervention.
Cannot have received: PARP inhibitor
Prior treatment for prostate cancer at any stage with...poly ADP-ribose polymerase (PARP) monotherapy
Cannot have received: systemic anti-cancer treatment
Prior treatment for prostate cancer at any stage with...other systemic anti-cancer treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Urology Centers of Alabama · Homewood, Alabama
- Ironwood Cancer & Research Centers · Chandler, Arizona
- Ironwood Cancer & Research Centers · Gilbert, Arizona
- Ironwood Cancer & Research Centers · Glendale, Arizona
- Ironwood Cancer & Research Centers · Mesa, Arizona
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify